"Finasteride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.
| Descriptor ID |
D018120
|
| MeSH Number(s) |
D04.210.500.054.079.500 D04.210.500.925.100.250
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Finasteride".
Below are MeSH descriptors whose meaning is more specific than "Finasteride".
This graph shows the total number of publications written about "Finasteride" by people in this website by year, and whether "Finasteride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Finasteride" by people in Profiles.
-
Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022; 33(1):65-76.
-
Differential Gene Expression in Post-Finasteride Syndrome Patients. J Sex Med. 2021 09; 18(9):1479-1490.
-
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93.
-
Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences. Prostate. 2015 Oct; 75(14):1643-61.
-
Finasteride and methadone use and risk of advanced hepatitis C related liver disease. Dig Dis Sci. 2012 Nov; 57(11):3004-10.
-
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer. 2008 Mar 01; 112(5):1058-65.
-
The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev. 2006 Aug; 15(8):1485-9.
-
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol. 2005 Mar 20; 23(9):1911-20.
-
The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol. 2002 May; 167(5):2105-8.
-
Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology. 1998 Aug; 52(2):195-201; discussion 201-2.